Wiley Blackwell

SHERPA: Unknown

People

  1. Horwitz
    Horwitz
  2. Kumar
    Kumar
  3. Zelenetz
    Zelenetz
  4. Hamlin
    Hamlin
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Palomba
    Palomba
  8. Drullinsky
    Drullinsky
  9. Yahalom
    Yahalom
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Lymphoma (26)
  5. Survivorship Research (26)
  6. Epidemiology and Biostatistics (15)
  7. Population Sciences Research Program (13)
  8. Biostatistics Service (12)
  9. Executive Committee, Center for Hematologic Malignancies (11)
  10. Hematology-Oncology Fellows (11)
Search Within
  1. "Matthew Matasar"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (3)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Lymphoma (26)
  5. Survivorship Research (26)
  6. Epidemiology and Biostatistics (15)

More Groups

People
  1. Matthew Matasar (26)
  2. David Straus (12)
  3. Anas Younes (11)
  4. Andrew Zelenetz (11)
  5. Anita Kumar (11)
  6. Steven Horwitz (11)

More People

Years
  1. 2021 (6)
  2. 2019 (8)
  3. 2018 (2)
  4. 2017 (9)
  5. 2016 (1)
Publications
  1. Hematological Oncology (22)
  2. Journal of the American Heart Association (2)
  3. Cancer (1)
  4. The American Cancer Society's Principles of Oncology: Prevention to Survivorship (1)

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Prognostic significance of time from last therapy in patients with diffuse large B‐cell lymphoma: Retrospective analysis of electronic health records and claims data in the US
    Meeting Abstract

    Matasar, M.; Castro, F.; Liu, Y.; Abraham, A.; Oki, Y.; Dickinson, M.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Preliminary activity of devimistat (CPI 613) in patients with relapsed or refractory Burkitt lymphoma/leukemia
    Meeting Abstract

    Nikolaenko, L.; Pardee, T. S.; Steiner, R.; Abramson, J. S.; Horwitz, S.; Matasar, M.; Owens, C.; Rodriguez-Rivera, I.; Straus, D.; Luther, S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • ESCALADE: A phase 3 study of acalabrutinib in combination with R‐CHOP for patients ≤65y with untreated non‐germinal center B‐cell–like diffuse large B‐cell lymphoma
    Meeting Abstract

    Sehn, L. H.; Kahl, B.; Matasar, M.; Lentz, G.; Izutsu, K.; Zhao, W.; Tao, L.; Calvo, R.; Zinzani, P. L.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • An ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Kim, W. S.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Budde, L. E.; Cheah, C.; Gregory, G. P.; Hong, J.; Ku, M.; Marlton, P.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Real‐world assessment of practice efficiency with the introduction of subcutaneous rituximab
    Meeting Abstract

    Matasar, M. J.; Qiu, A.; Shapouri, S.; Drill, E. N.; Schade, J.; Ravelo, A.; Ni, A.; To, T. M.; Dawson, K. L.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step‐up dosing of mosunetuzumab in relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL)
    Meeting Abstract

    Sehn, L. H.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Diefenbach, C. M.; Flinn, I.; Hong, J. Y.; Kim, W. S.; Matasar, M.; Nastoupil, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save